Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Hims & Hers projects weight loss business to hit $725M in 2025 despite GLP-1 market shift
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations and gave upbeat guidance for 2025. | Hims & Hers' business is booming and the company projected 2025 revenue to hit $2.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...
Hims & Hers faces new headwinds in its weight management segment with the Food and Drug Administration ending the shortage of ...
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback